National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

About | Ordering | New

Menu menu

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

Review of the Centers for Disease Control and Prevention's Smallpox Vaccination Program Implementation: Letter Report 3 (2003)
Board on Health Promotion and Disease Prevention (HPDP)
 Institute of Medicine (IOM)

Citation Manager

. "General Comments." Review of the Centers for Disease Control and Prevention's Smallpox Vaccination Program Implementation: Letter Report 3. Washington, DC: The National Academies Press, 2003.

Please select a format:

BibTeX EndNote RefMan
Page
1
bottomleft bottomright
  E-mail
Share on facebook Facebook
Share on delicious Delicious
Share on stumbleupon Stumble
Share on twitter Twitter
More Sharing ServicesMore

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

REVIEW OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION’S SMALLPOX VACCINATION PROGRAM IMPLEMENTATION

Letter Report #3

May 23, 2003

Dr. Julie Gerberding

Director

Centers for Disease Control and Prevention

1600 Clifton Road, NE Atlanta, GA30333

Dear Dr. Gerberding:

The Committee on Smallpox Vaccination Program Implementation is pleased to offer you our third letter report in a series of brief reports providing advice to the Centers for Disease Control and Prevention (CDC) on the implementation of the pre-event smallpox vaccination program. In addition to some general comments about program activities, the committee would like to draw your attention to two main issues:

  1. Considerations for next steps in the pre-event vaccination program, and

  2. The smallpox components of the Continuation Guidance for the Cooperative Agreement on Public Health Preparedness and Response for Bioterrorism—Budget Year Four detailed in Program Announcement 99051 (DHHS, 2003a).1

In particular, the committee would like to reaffirm the need for a pause in the program, before the vaccine is offered more widely, and also make some specific suggestions about the recently issued guidance. In a forthcoming report, the committee intends to focus on issues surrounding definitions and measurements of smallpox preparedness, and its integration into broader bioterrorism readiness. The committee will also discuss screening and follow-up issues relevant to the continuation of the vaccination program, and answer specific questions asked by CDC and its partners at the May 1, 2003 committee meeting.

General Comments

The committee reiterates its high regard for CDC and its partners, and the remarkable amount of work completed in the national smallpox vaccination program, especially in the context of additional strain on all resources caused by the emergence and spread of Severe Acute Respiratory Syndrome (SARS). In fact, the committee heard from program administrators that

1  

The guidance was issued on May 2, 2003, after the release of the committee’s second report on March 27, 2003. State applications are due July 1, 2003.
Page
1

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 1
REVIEW OF THE CENTERS FOR DISEASE CONTROL AND PREVENTION’S SMALLPOX VACCINATION PROGRAM IMPLEMENTATION Letter Report #3 May 23, 2003 Dr. Julie Gerberding Director Centers for Disease Control and Prevention 1600 Clifton Road, NE Atlanta, GA30333 Dear Dr. Gerberding: The Committee on Smallpox Vaccination Program Implementation is pleased to offer you our third letter report in a series of brief reports providing advice to the Centers for Disease Control and Prevention (CDC) on the implementation of the pre-event smallpox vaccination program. In addition to some general comments about program activities, the committee would like to draw your attention to two main issues: Considerations for next steps in the pre-event vaccination program, and The smallpox components of the Continuation Guidance for the Cooperative Agreement on Public Health Preparedness and Response for Bioterrorism—Budget Year Four detailed in Program Announcement 99051 (DHHS, 2003a).1 In particular, the committee would like to reaffirm the need for a pause in the program, before the vaccine is offered more widely, and also make some specific suggestions about the recently issued guidance. In a forthcoming report, the committee intends to focus on issues surrounding definitions and measurements of smallpox preparedness, and its integration into broader bioterrorism readiness. The committee will also discuss screening and follow-up issues relevant to the continuation of the vaccination program, and answer specific questions asked by CDC and its partners at the May 1, 2003 committee meeting. General Comments The committee reiterates its high regard for CDC and its partners, and the remarkable amount of work completed in the national smallpox vaccination program, especially in the context of additional strain on all resources caused by the emergence and spread of Severe Acute Respiratory Syndrome (SARS). In fact, the committee heard from program administrators that 1   The guidance was issued on May 2, 2003, after the release of the committee’s second report on March 27, 2003. State applications are due July 1, 2003.

Representative terms from entire chapter:

smallpox vaccination